Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2126 - 2150 of 15116 in total
Sulodexide is a mixture of glycosaminoglycans (GAGs) composed of dermatan sulfate (DS) and fast moving heparin (FMH).
Approved
Investigational
Matched Description: … Sulodexide is a mixture of glycosaminoglycans (GAGs) composed of dermatan sulfate (DS) and fast moving …
Matched Categories: … Heparin and similars ... Blood and Blood Forming Organs …
As a diuretic, cyclothiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like cyclothiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter....
Approved
Matched Description: … corticosteroid and estrogen therapy. ... tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and ... indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and
Matched Categories: … cyclothiazide and potassium ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Revefenacin is a novel biphenyl carbamate tertiary amine agent that belongs to the family of the long-acting muscarinic antagonists (LAMA). The labile primary amide in the structure produces a "soft-drug" site that allows rapid systemic clearance and minimizing of the systemically mediated adverse reactions. The LAMA group falls into a...
Approved
Investigational
Matched Description: … [A40026] It was developed by Theravance Biopharma and FDA approved on November 9, 2018.[L4818] ... The LAMA group falls into a parent category known as long-acting inhaled bronchodilators and this type ... labile primary amide in the structure produces a "soft-drug" site that allows rapid systemic clearance and
Novartis' brand name Zelnorm (tegaserod) had originally received approval from the US FDA in 2002 for the treatment of irritable bowel syndrome with constipation (IBS-C).[L5918,F4229] It was, however, voluntarily withdrawn from widespread use in the US market in 2007 after concerns arose over the possibility that tegaserod could potentially cause...
Approved
Investigational
Withdrawn
Matched Description: … the unique mechanism of action of acting on serotonin-4 (5-HT(4)) receptors in smooth muscle cells and ... the gastrointestinal wall to facilitate actions like esophageal relaxation, peristaltic gut movement, and ... re-approval' of tegaserod for treatment of IBS-C specifically in female patients less than 65 years of age and
Matched Categories: … Alimentary Tract and Metabolism …
Dienestrol is a synthetic, non-steroidal estrogen. It is an estrogen receptor agonist. Estrogens work partly by increasing a normal clear discharge from the vagina and making the vulva and urethra healthy. Using or applying an estrogen relieves or lessens: dryness and soreness in the vagina, itching, redness, or soreness of...
Approved
Investigational
Matched Description: … Estrogens work partly by increasing a normal clear discharge from the vagina and making the vulva and ... Using or applying an estrogen relieves or lessens: dryness and soreness in the vagina, itching, redness ... include a genital skin condition (vulvar atrophy), inflammation of the vagina (atrophic vaginitis), and
Matched Categories: … Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic disease-modifying anti-rheumatic drug (bDMARDs) that...
Approved
Investigational
Matched Description: … and subcutaneous formulations of the drug based on the dosing schedule and condition being treated. ... the interleukin (IL)-12 and IL-23 cytokines. ... IL-23, which are cytokines that are involved in immune and inflammatory responses. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Skin and Mucous Membrane Agents ... Antineoplastic and Immunomodulating Agents …
Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients...
Approved
Matched Description: … Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various ... Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and
Matched Categories: … Heparin and similars ... Blood and Blood Forming Organs …
Nadroparin is a low molecular weight heparin (LMWH) which, when bound to antithrombin III (ATIII), accelerates the inactivation of factor II and factor Xa. Nadroparin halts the coagulation pathway by inhibiting the activation of thrombin (factor IIa) by factor Xa. The amplification of the fibrin clotting cascade is stopped once...
Approved
Investigational
Matched Description: … It is derived from porcine sources and has a mean molecular size of 5000 daltons. ... heparin (LMWH) which, when bound to antithrombin III (ATIII), accelerates the inactivation of factor II and ... The amplification of the fibrin clotting cascade is stopped once factors Xa and IIa are inactivated. …
Matched Categories: … Heparin and similars ... Blood and Blood Forming Organs …
Parnaparin is an heparin of low molecular weight with antithrombotic effects.
Approved
Investigational
Matched Categories: … Heparin and similars ... Blood and Blood Forming Organs …
Tagraxofusp is a CD123-directed cytotoxin. It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in Escherichia coli.[A253762, A253887, L43702] Tagraxofusp received its first global approval by the FDA on December 21, 2018...
Approved
Investigational
Matched Description: … fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the...
Approved
Matched Description: … and proteolysis. ... tissues such as the liver, fat cells, and skeletal muscle. ... addition of two arginines to the C-terminus (positions B31 and 32) of the B-chain. …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... insulin glargine and lixisenatide ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate control, rhythm control, prevention...
Approved
Matched Description: … toxicities, such as thyroid and pulmonary toxicities. ... calcium ion channels and inhibiting β-adrenergic receptors. ... It is managed by rate control, rhythm control, prevention of thromboembolic events, and treatment of …
Approved
Experimental
Matched Iupac: … 2-({[(3-bromo-2,4,6-trimethylphenyl)carbamoyl]methyl}(carboxymethyl)amino)acetic acid
Matched Categories: … Amino Acids, Peptides, and Proteins …
Donislecel is the first allogeneic pancreatic islet cellular from deceased donor pancreatic cells used for the treatment of adult type 1 diabetes with unsuccessful control of glycated hemoglobin, despite intensive diabetes management and treatments.[L47166,L47196] The primary mechanism of action of donislecel is attributed to the secretion of insulin and other...
Approved
Matched Description: … 1 diabetes with unsuccessful control of glycated hemoglobin, despite intensive diabetes management and ... other pancreatic hormones from infused allogeneic islet cells to mimic endogenous glucose control and ... L47166,L47196] The primary mechanism of action of donislecel is attributed to the secretion of insulin and
Matched Categories: … Cellular and Gene Therapy …
Long-acting, broad-spectrum, water-soluble, cephalexin derivative.
Approved
Vet approved
Withdrawn
Matched Iupac: … amino-2-(4-hydroxyphenyl)acetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Cefprozil is a cephalosporin antibiotic that is commonly employed to treat a variety of bacterial infections, including those of the ear and skin, bronchitis, and others.
Approved
Matched Iupac: … -hydroxyphenyl)acetamido]-8-oxo-3-(prop-1-en-1-yl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Matched Description: … skin, bronchitis, and others. ... antibiotic that is commonly employed to treat a variety of bacterial infections, including those of the ear and
Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
Approved
Matched Description: … It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children …
Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it...
Approved
Investigational
Matched Description: … [A38834] It is the prodrug form of isavuconazole, the active moiety, and it is available in oral and ... Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July ... 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed …
Matched Categories: … Isavuconazole and Prodrugs …
Avibactam is a non-β-lactam β-lactamase inhibitor that is available in combination with ceftazidime (Avycaz). This combination was approved by the FDA on February 25, 2015 for the treatment of complicated intra-abdominal infections in combination with metronidazole, and the treatment of complicated urinary tract infections, including pyelonephritis caused by antibiotic resistant-pathogens,...
Approved
Matched Iupac: … [(2S,5R)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl]oxidanesulfonic acid
Matched Description: … 2015 for the treatment of complicated intra-abdominal infections in combination with metronidazole, and ... As there is limited clinical safety and efficacy data, Avycaz should be reserved for patients over 18 …
Radiopaque medium usually in oil; used in bronchography.
Approved
Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability,...
Approved
Investigational
Matched Description: … , and migration of human endothelial cells. ... By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby ... VEGFR stimulation also mediates downstream signalling required for angiogenesis and is postulated to …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Buserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR). It is used in prostate cancer treatment.
Approved
Investigational
Matched Categories: … Hormones and Related Agents ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Artemotil, also known as β-arteether, is a semi-synthetic derivative of artemisinin and a fast acting blood schizonticide specifically indicated for the treatment of chloroquine-resistant Plasmodium falciparum malaria and cerebral malaria cases.
Approved
Matched Description: … Artemotil, also known as β-arteether, is a semi-synthetic derivative of artemisinin and a fast acting ... schizonticide specifically indicated for the treatment of chloroquine-resistant _Plasmodium falciparum_ malaria and
Matched Categories: … Artemisinin and derivatives ... Antiparasitic Products, Insecticides and Repellents …
Tebentafusp is a gp100 peptide-HLA-directed CD3 T cell engager. It is a bispecific, fusion protein and first-in-class drug of immune-mobilizing monoclonal T cell receptors against cancer (ImmTACs), a recently developed cancer immunotherapy with a novel mechanism of action. ImmTACs bind to target cancer cells that express a specific antigen of...
Approved
Investigational
Matched Description: … [L39995] It is a bispecific, fusion protein and first-in-class drug of immune-mobilizing monoclonal T ... ImmTACs bind to target cancer cells that express a specific antigen of interest and recruit cytotoxic ... being the first and only therapy for the treatment of unresectable or metastatic uveal melanoma to be …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Ceftolozane is a semi-synthetic broad-spectrum fifth generation cephalosporin. It was approved by the FDA in 2014 for use in combination with Tazobactam for the treatment of serious infections, such as intra-abdominal infections and complicated urinary tract infections. The manufacturer of this drug is Cubist Pharmaceuticals. Most recently, in June 2019,...
Approved
Investigational
Matched Description: … and mortality in hospitalized patients and the use of ceftolozane-tazobactam offers effective activity ... 2019, ceftolozane-tazobactam was approved for the treatment of hospital-acquired bacterial pneumonia and ... combination with [Tazobactam] for the treatment of serious infections, such as intra-abdominal infections and
Displaying drugs 2126 - 2150 of 15116 in total